Calcium-Collagen Chelate: Evidence for Bone Reversal Properties


A study published in the Journal of Medicinal Food in March 2015 showed:

“that a 3-month intervention using a calcium-collagen chelate (CC) dietary supplement was efficacious in improving bone mineral density (BMD) and blood biomarkers of bone turnover in osteopenic postmenopausal women. This study reports the long-term efficacy of CC in reducing bone loss in postmenopausal women with osteopenia.” 

The authors of the study concluded that:

“these results support the use of calcium collagen chelate in reducing bone loss in osteopenic postmenopausal women.”

KoACTTM is a patented compound of collagen peptides and calcium. This unique ingredient was found to increase both bone strength and bone mineral density in a preclinical animal studies and a recently completed human study. *

KoACTTM is has been awarded three US patents 7,495,076; 7,608,588; 7,759,310.

A human clinical trial has been conducted at Florida State University with Dr. Bahram H. Arjmandi, PhD, RD. Dr. Arjmandi is the Margaret A. Sitton Professor and Chair of the Department of Nutrition, Food, and Exercise Sciences at FSU.

KoACTTM significantly improved bone metabolic balance indicator, BAP/TRAP5b ratio, while calcium did not. This improved bone metabolism is likely through improved bone synthesis and reduced bone resorption, as evidenced via increased Bone synthesis biomarkers: BAP and CICP, and reduced bone resorption bone biomarker: TRAP.


A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial.

Evidence for Bone Reversal Properties of a Calcium- Collagen Chelate, a Novel Dietary Supplement


KoACTTM Calcium Collagen Chelate – Swansons


    Print This Post Print This Post